News

The randomized, double-blinded, dose-ranging, placebo-controlled Phase 2 trial will evaluate the safety and efficacy of a single, bilateral application of RT001 topical gel for the treatment of primary

US-based New Science Ventures led the financing round, which also included Belgian investors VIVES Louvain Technology Fund, NivelInvest, Fund+, Integrale, SRIW, SFPI-FPIM, Epimède and other individual participants. The

The company’s EySite-NanoM is a sustained-release delivery system designed to offer continuous release of its therapeutic anti-glaucoma agent for preventing the peak and trough drug levels that take

Daratumumab is an investigational, human anti-CD38 monoclonal antibody, which is designed to treat patients with relapsed and refractory multiple myeloma. Multiple myeloma is an incurable blood cancer that

The partnership harnesses Certara’s unmatched biosimulation (modeling and simulation) and regulatory writing capabilities, with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges

The proceeds will be used to advance the company’s ongoing spinal muscular atrophy (SMA) clinical program and expand key operational capabilities. The Class D financing was led by

Medidata Clinical Cloud platform will enhance data management capabilities and drive biomedical innovation in the development of a pneumococcal conjugate vaccine for infants. Walvax is using Medidata Rave

The Phase I study, conducted in France, assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of SCYX-7158 after single oral ascending doses in 128 healthy human volunteers of sub-Saharan

Insulin glargine 300 units/mL is a concentrated formulation of the glargine molecule identified in Lantus (insulin glargine 100 units/mL). It forms a compact subcutaneous depot with a reduced